Shopping Cart 0
Cart Subtotal

Myriad Genetics Inc (MYGN) - Product Pipeline Analysis, 2018 Update

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 750

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 1500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 2250
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies



Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company's product portfolio includes molecular diagnostic testing products that analyze genes, their expression levels and corresponding proteins to assess a person risk for developing disease later in life, accurately diagnose disease and determine a patient's likelihood of responding to a particular drug. It also provides an array of pharmaceutical and clinical services. Myriad markets its products through its sales force in Europe and Canada and through distributor agreements in Latin American, Middle Eastern, Asian and African countries. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, the Netherlands and Italy. Myriad is headquartered in Salt Lake City, Utah, the US.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.


- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company Myriad Genetics Inc

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company


Table Of Content


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Myriad Genetics Inc Company Overview 7

Myriad Genetics Inc Company Snapshot 7

Myriad Genetics Inc Pipeline Products and Ongoing Clinical Trials Overview 7

Myriad Genetics Inc-Pipeline Analysis Overview 10

Business Description 10

Myriad Genetics Inc-Key Facts 10

Myriad Genetics Inc-Major Products and Services 11

Myriad Genetics Inc Pipeline Products by Development Stage 13

Myriad Genetics Inc Ongoing Clinical Trials by Trial Status 16

Myriad Genetics Inc Pipeline Products Overview 18

BRACAnalysis CDx-Talazoparib 18

BRACAnalysis CDx-Talazoparib Product Overview 18

ChemoPredict Test 19

ChemoPredict Test Product Overview 19

Diagnostic Assay -Lung Cancer 20

Diagnostic Assay -Lung Cancer Product Overview 20

Diagnostic Assay-HER2+/TNBC-Breast Cancer 21

Diagnostic Assay-HER2+/TNBC-Breast Cancer Product Overview 21

Diagnostic Assay-Juvenile Idiopathic Rheumatoid Arthritis 22

Diagnostic Assay-Juvenile Idiopathic Rheumatoid Arthritis Product Overview 22

Diagnostic Assay-Melanoma 23

Diagnostic Assay-Melanoma Product Overview 23

Diagnostic Assay-Prostate Cancer 24

Diagnostic Assay-Prostate Cancer Product Overview 24

Diagnostic Test-Alzheimer's Disease 25

Diagnostic Test-Alzheimer's Disease Product Overview 25

Diagnostic Test-Colon Cancer 26

Diagnostic Test-Colon Cancer Product Overview 26

Diagnostic Test-Kidney Damage 27

Diagnostic Test-Kidney Damage Product Overview 27

GeneSight Test-MDD 28

GeneSight Test-MDD Product Overview 28

GeneSight Test-MDD Clinical Trial 29

Genetic Risk Score Test 30

Genetic Risk Score Test Product Overview 30

Genetic Risk Score Test Clinical Trial 31

HRD Companion Diagnostic Test-Breast Cancer 32

HRD Companion Diagnostic Test-Breast Cancer Product Overview 32

Kidney Transplant Rejection Test 33

Kidney Transplant Rejection Test Product Overview 33

Multi-Biomarker Test-Ankylosing Spondylitis 34

Multi-Biomarker Test-Ankylosing Spondylitis Product Overview 34

Multi-Biomarker Test-Autoimmune Diseases 35

Multi-Biomarker Test-Autoimmune Diseases Product Overview 35

Multi-Biomarker Test-Inflammatory Diseases 36

Multi-Biomarker Test-Inflammatory Diseases Product Overview 36

Multi-Biomarker Test-Psoriatic Arthritis 37

Multi-Biomarker Test-Psoriatic Arthritis Product Overview 37

Multi-Biomarker Test-Systemic Lupus Erythematosus 38

Multi-Biomarker Test-Systemic Lupus Erythematosus Product Overview 38

myChoice Diabetes 39

myChoice Diabetes Product Overview 39

myChoice HRD (PARP)-Niraparib 40

myChoice HRD (PARP)-Niraparib Product Overview 40

myChoice HRD (PARP)-Niraparib Clinical Trial 41

myChoice HRD (PARP)-Talazoparib 43

myChoice HRD (PARP)-Talazoparib Product Overview 43

myChoice HRD (PARP)-Talazoparib Clinical Trial 44

myChoice HRD (Platinum) 45

myChoice HRD (Platinum) Product Overview 45

myChoice HRD (Platinum) Clinical Trial 46

myPath BiPolar 47

myPath BiPolar Product Overview 47

myPath Endometriosis 48

myPath Endometriosis Product Overview 48

myPath Pancreatic Cancer 49

myPath Pancreatic Cancer Product Overview 49

myPath Prostate Cancer 50

myPath Prostate Cancer Product Overview 50

myPath Psoriatic Arthritis 51

myPath Psoriatic Arthritis Product Overview 51

myPlan Renal Cancer 52

myPlan Renal Cancer Product Overview 52

myRisk Schizophrenia 53

myRisk Schizophrenia Product Overview 53

Prognostic Test-Bladder Cancer 54

Prognostic Test-Bladder Cancer Product Overview 54

SanoPredict 55

SanoPredict Product Overview 55

Tumor BRACAnalysis CDx-Veliparib 56

Tumor BRACAnalysis CDx-Veliparib Product Overview 56

VeriPsych Test-Bipolar Disorder 57

VeriPsych Test-Bipolar Disorder Product Overview 57

Myriad Genetics Inc-Key Competitors 58

Myriad Genetics Inc-Key Employees 59

Myriad Genetics Inc-Key Employee Biographies 60

Myriad Genetics Inc-Locations And Subsidiaries 61

Head Office 61

Other Locations & Subsidiaries 61

Recent Developments 63

Myriad Genetics Inc, Recent Developments 63

Jul 18, 2018: Myriad announces coverage decision by Kroger Prescription Plans for Vectra DA 63

Jun 28, 2018: BRACAnalysis CDx Identifies Patients Who Respond to Lynparza in SOLO-1 Study 63

Jun 21, 2018: Top-Five National Payer Issues Positive Coverage Decision for Myriad's Prolaris Test for Prostate Cancer 63

Jun 18, 2018: Myriad's BRACAnalysis CDx Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Talazoparib in Metastatic Breast Cancer 64

Jun 06, 2018: Crescendo Bioscience Announces Four Studies with Vectra DA Will Be Featured at the 2018 European League Against Rheumatism Annual Meeting 64

Jun 01, 2018: Myriad Genetics Presents Second Pivotal Validation Study for riskScore Test at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 65

May 31, 2018: GeneSight Guided Treatment Significantly Improves Outcomes for Patients with Major Depression Treated in the Primary Care Setting 66

May 23, 2018: Myriad Announces Seven New Payer Coverage Decisions for Prolaris 67

May 15, 2018: Myriad Genetics to Present Eight Studies at the 2018 American Society of Clinical Oncology Annual Meeting 67

May 15, 2018: New Publication on Counsyl's Foresight Carrier Screen Validates the Highly Accurate Detection of Couples At-Risk for Children With Serious Disease 69

Appendix 71

Methodology 71

About GlobalData 74

Contact Us 74

Disclaimer 74

List Of Figure

List of Figures

Myriad Genetics Inc Pipeline Products by Equipment Type 8

Myriad Genetics Inc Pipeline Products by Development Stage 13

Myriad Genetics Inc Ongoing Clinical Trials by Trial Status 16

List Of Table

List of Tables

Myriad Genetics Inc Pipeline Products and Ongoing Clinical Trials Overview 7

Myriad Genetics Inc Pipeline Products by Equipment Type 8

Myriad Genetics Inc Pipeline Products by Indication 9

Myriad Genetics Inc Ongoing Clinical Trials by Trial Status 9

Myriad Genetics Inc, Key Facts 10

Myriad Genetics Inc, Major Products and Services 11

Myriad Genetics Inc Number of Pipeline Products by Development Stage 13

Myriad Genetics Inc Pipeline Products Summary by Development Stage 14

Myriad Genetics Inc Ongoing Clinical Trials by Trial Status 16

Myriad Genetics Inc Ongoing Clinical Trials Summary 17

BRACAnalysis CDx-Talazoparib-Product Status 18

BRACAnalysis CDx-Talazoparib-Product Description 18

ChemoPredict Test-Product Status 19

ChemoPredict Test-Product Description 19

Diagnostic Assay -Lung Cancer-Product Status 20

Diagnostic Assay -Lung Cancer-Product Description 20

Diagnostic Assay-HER2+/TNBC-Breast Cancer-Product Status 21

Diagnostic Assay-HER2+/TNBC-Breast Cancer-Product Description 21

Diagnostic Assay-Juvenile Idiopathic Rheumatoid Arthritis-Product Status 22

Diagnostic Assay-Juvenile Idiopathic Rheumatoid Arthritis-Product Description 22

Diagnostic Assay-Melanoma-Product Status 23

Diagnostic Assay-Melanoma-Product Description 23

Diagnostic Assay-Prostate Cancer-Product Status 24

Diagnostic Assay-Prostate Cancer-Product Description 24

Diagnostic Test-Alzheimer's Disease-Product Status 25

Diagnostic Test-Alzheimer's Disease-Product Description 25

Diagnostic Test-Colon Cancer-Product Status 26

Diagnostic Test-Colon Cancer-Product Description 26

Diagnostic Test-Kidney Damage-Product Status 27

Diagnostic Test-Kidney Damage-Product Description 27

GeneSight Test-MDD-Product Status 28

GeneSight Test-MDD-Product Description 28

GeneSight Test-MDD-PRIME Care (Precision Medicine In Mental Health Care) 29

Genetic Risk Score Test-Product Status 30

Genetic Risk Score Test-Product Description 30

Genetic Risk Score Test-Clinical Trial to Examine Use of Predictive Genetic Tests for Cancer Risks Assessment 31

HRD Companion Diagnostic Test-Breast Cancer-Product Status 32

HRD Companion Diagnostic Test-Breast Cancer-Product Description 32

Kidney Transplant Rejection Test-Product Status 33

Kidney Transplant Rejection Test-Product Description 33

Multi-Biomarker Test-Ankylosing Spondylitis-Product Status 34

Multi-Biomarker Test-Ankylosing Spondylitis-Product Description 34

Multi-Biomarker Test-Autoimmune Diseases-Product Status 35

Multi-Biomarker Test-Autoimmune Diseases-Product Description 35

Multi-Biomarker Test-Inflammatory Diseases-Product Status 36

Multi-Biomarker Test-Inflammatory Diseases-Product Description 36

Multi-Biomarker Test-Psoriatic Arthritis-Product Status 37

Multi-Biomarker Test-Psoriatic Arthritis-Product Description 37

Multi-Biomarker Test-Systemic Lupus Erythematosus-Product Status 38

Multi-Biomarker Test-Systemic Lupus Erythematosus-Product Description 38

myChoice Diabetes-Product Status 39

myChoice Diabetes-Product Description 39

myChoice HRD (PARP)-Niraparib-Product Status 40

myChoice HRD (PARP)-Niraparib-Product Description 40

myChoice HRD (PARP)-Niraparib-A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy 41

myChoice HRD (PARP)-Niraparib-A Phase II, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens 41

myChoice HRD (PARP)-Niraparib-Phase I of Bevacizumab-Niraparib Combination. AVANOVA2 -A 3-arm, Phase II Randomized Study of Niraparib &/or Niraparib-bevacizumab Combination Against Bevacizumab Alone in HRD Platinum-sensitive Epithelial Ovarian Cancer: AVANOVA1 42

myChoice HRD (PARP)-Talazoparib-Product Status 43

myChoice HRD (PARP)-Talazoparib-Product Description 43

myChoice HRD (PARP)-Talazoparib-A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild-type Patients with (i) Advanced Triple-negative Breast Cancer and Homologous Recombination Deficiency, and (ii) Advanced HER2-negative Breast Cancer or Other Solid Tumors with Either a Mutation in Homologous Recombination Pathway Genes 44

myChoice HRD (Platinum)-Product Status 45

myChoice HRD (Platinum)-Product Description 45

myChoice HRD (Platinum)-A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker 46

myPath BiPolar-Product Status 47

myPath BiPolar-Product Description 47

myPath Endometriosis-Product Status 48

myPath Endometriosis-Product Description 48

myPath Pancreatic Cancer-Product Status 49

myPath Pancreatic Cancer-Product Description 49

myPath Prostate Cancer-Product Status 50

myPath Prostate Cancer-Product Description 50

myPath Psoriatic Arthritis-Product Status 51

myPath Psoriatic Arthritis-Product Description 51

myPlan Renal Cancer-Product Status 52

myPlan Renal Cancer-Product Description 52

myRisk Schizophrenia-Product Status 53

myRisk Schizophrenia-Product Description 53

Prognostic Test-Bladder Cancer-Product Status 54

Prognostic Test-Bladder Cancer-Product Description 54

SanoPredict-Product Status 55

SanoPredict-Product Description 55

Tumor BRACAnalysis CDx-Veliparib-Product Status 56

Tumor BRACAnalysis CDx-Veliparib-Product Description 56

VeriPsych Test-Bipolar Disorder-Product Status 57

VeriPsych Test-Bipolar Disorder-Product Description 57

Myriad Genetics Inc, Key Employees 59

Myriad Genetics Inc, Key Employee Biographies 60

Myriad Genetics Inc, Subsidiaries 61

Glossary 73

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to

Products and Companies


Myriad Genetics Inc, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies


Siemens Healthcare GmbH

Nanosphere Inc

Hologic Inc

Exact Sciences Corp

Amgen Inc

Affymetrix, Inc.

Abbott Laboratories